Curative Biotechnology Inc (CUBT) - Net Assets
Based on the latest financial reports, Curative Biotechnology Inc (CUBT) has net assets worth $-4.99 Million USD as of March 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($2.29 Million) and total liabilities ($7.28 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read Curative Biotechnology Inc (CUBT) total liabilities for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-4.99 Million |
| % of Total Assets | -218.54% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Curative Biotechnology Inc - Net Assets Trend (2013–2024)
This chart illustrates how Curative Biotechnology Inc's net assets have evolved over time, based on quarterly financial data. Also explore Curative Biotechnology Inc assets under control for the complete picture of this company's asset base.
Annual Net Assets for Curative Biotechnology Inc (2013–2024)
The table below shows the annual net assets of Curative Biotechnology Inc from 2013 to 2024. For live valuation and market cap data, see market cap of Curative Biotechnology Inc.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-4.91 Million | -56.32% |
| 2023-12-31 | $-3.14 Million | +84.69% |
| 2022-12-31 | $-20.53 Million | -25.47% |
| 2021-12-31 | $-16.36 Million | -261.85% |
| 2020-12-31 | $-4.52 Million | -1165.40% |
| 2019-12-31 | $-357.33K | +48.16% |
| 2018-12-31 | $-689.28K | -4.54% |
| 2017-12-31 | $-659.37K | -3.61% |
| 2016-12-31 | $-636.38K | -2.81% |
| 2015-12-31 | $-618.98K | +20.01% |
| 2014-12-31 | $-773.80K | -9.87% |
| 2013-12-31 | $-704.28K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Curative Biotechnology Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3785020100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $91.93K | % |
| Other Components | $36.88 Million | % |
| Total Equity | $-4.91 Million | 100.00% |
Curative Biotechnology Inc Competitors by Market Cap
The table below lists competitors of Curative Biotechnology Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Viji Finance Limited
NSE:VIJIFIN
|
$6.98 Million |
|
Biomind Labs Inc
NEO:BMND
|
$6.98 Million |
|
Kanger International Bhd
KLSE:0170
|
$6.98 Million |
|
IP Group
LSE:IPO
|
$6.99 Million |
|
Plascar Participações Industriais S.A
SA:PLAS3
|
$6.97 Million |
|
Ignite Ltd
AU:IGN
|
$6.96 Million |
|
Babylon Pump & Power Ltd
AU:BPP
|
$6.96 Million |
|
Nisun International Enterprise Development Group Co Ltd
NASDAQ:NISN
|
$6.96 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Curative Biotechnology Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -3,142,625 to -4,912,611, a change of -1,769,986.
- Net loss of 3,565,000 reduced equity.
- Other factors increased equity by 1,795,014.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-3.56 Million | -72.57% |
| Other Changes | $1.80 Million | +36.54% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Curative Biotechnology Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | $0.00 | $1.21 | x |
| 2014-12-31 | $0.00 | $1.21 | x |
| 2015-12-31 | $0.00 | $1.21 | x |
| 2016-12-31 | $0.00 | $1.21 | x |
| 2017-12-31 | $0.00 | $1.21 | x |
| 2018-12-31 | $0.00 | $1.21 | x |
| 2019-12-31 | $0.00 | $1.21 | x |
| 2020-12-31 | $0.00 | $1.21 | x |
| 2021-12-31 | $0.01 | $1.21 | x |
| 2022-12-31 | $0.00 | $1.21 | x |
| 2023-12-31 | $0.00 | $1.21 | x |
| 2024-12-31 | $-0.01 | $1.21 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Curative Biotechnology Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-50.64%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 0.00% | -19.50% | 1.42x | 0.00x | $7.29K |
| 2014 | 0.00% | -58.89% | 0.71x | 0.00x | $-538.90 |
| 2015 | 0.00% | 168.49% | 1.66x | 0.00x | $252.73K |
| 2016 | 0.00% | -156.88% | 0.17x | 0.00x | $46.24K |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $42.95K |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $39.01K |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $367.69K |
| 2020 | -290.22% | 0.00% | 0.00x | 1.41x | $-4.83 Million |
| 2021 | -317.51% | 0.00% | 0.00x | 1.43x | $-5.51 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.13 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.64 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.07 Million |
Industry Comparison
This section compares Curative Biotechnology Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $103,396,513
- Average return on equity (ROE) among peers: -329.31%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Curative Biotechnology Inc (CUBT) | $-4.99 Million | 0.00% | N/A | $6.97 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $118.45 Million |
| Abcellera Biologics Inc (ABCL) | $11.61 Million | 2.66% | 0.85x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $681.00K | -3192.95% | 12.43x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $184.86 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $40.92 Million | 73.18% | 0.29x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $-2.99 Million | 0.00% | 0.00x | $27.18 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.66 Million | -45.66% | 0.56x | $9.73 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $627.01 Million | -44.91% | 0.25x | $3.82 Billion |
About Curative Biotechnology Inc
Curative Biotechnology, Inc., a biopharmaceutical company, focuses on identifying, in licensing, and developing therapeutic drug candidates for rare disease indications. It develops Metformin Reformulation to treat intermediate dry macular degeneration and geographic atrophy; IMT504, a novel immunotherapy to treat late-stage rabies; and CUBT906, a fully humanized CD56 monoclonal antibody carrying… Read more